奥沙利铂联合长春瑞滨治疗耐药非小细胞肺癌

Oxaliplatin combined with vinorelbine in drug resistant non-small-cell lung cancer

目的:观察奥沙利铂(OXA)联合长春瑞滨(VRB)治疗耐药非小细胞肺癌(NSCLC)的疗效与毒副反应。方法:选择耐药晚期NSCLC 35例,给予OXA 100 mg/m2,VRB 25 mg/m2,第1天,经支气管动脉灌注。VRB 25mg/m2,第8天,经静脉注射。连用6个周期。结果:第6个周期末CR 1例,PR 14例,SD 13例,PD 7例。有效率为42.9%,毒性反应主要是外周感觉神经异常和白细胞减少。结论:奥沙利铂联合长春瑞滨治疗耐药晚期NSCLC的近期疗效明显,毒性反应可以耐受。经动脉用药可以明显提高近期缓解率,且可以减少外周感觉神经异常的毒副反应。

Purpose: To observe the efficacy and the side effects of oxaliplatin( OXA) in combination with vinorelbine (VRB) in the treatment of drug resistant non-small-cell lung cancer( NSCLC) . Methodii: Thirty-five patients with drug resistant lung cancer were treated by OXA + VRB. OXA 100 mg/m2, VRB 25 mg/m , on d 1, which were given by bronchial arteries injection, and VRB 25mg/m2 was given by venous injection on d 8. One cycle was given every 3 weeks and total six cycles was given. Results: There was 1 patient who showed completed remission( CR), 14 patients showed partial remission( PR), 13 patients showed stable disease( SD) and 7 patients showed progress disease( PD) after the sixth cycle. The response rate was 42. 9%. The major toxicities were peripheral sensory neuropathy and leukopenia. Conclusions: The regimen of OXA plus VRB is effective on drug resistant and advanced NSCLC and the side effects are tolerable. There is higher response rate and lower neurotoxicity when the medicines are given by arterial injection than by venous injection.